EU Parliament Pushes for Overhaul of Women's Healthcare Strategy

The European Parliament adopted a sweeping women's health report this week, pressing the European Commission to build an EU-wide strategy with dedicated funding to correct what rapporteur Billy Kelleher MEP (Fianna Fáil, Ireland) called decades of under-research and underfunding. The text, championed by the Renew Europe group, also reaffirms Parliament's support for enshrining the right to safe, legal and accessible abortion in the EU Charter of Fundamental Rights. For patients navigating fragmented care across borders, the vote signals that gender-blind medicine — from clinical trial design to the GP's office — is being elevated to a formal political priority.

What the report actually targets

The text identifies three structural gaps that shape day-to-day care: the under-representation of women in clinical trials, the absence of sex-disaggregated data in drug research, and the lack of gender-aware training among healthcare professionals. According to figures cited in the Renew Europe press materials, 72% of drug trial studies still fail to report results broken down by sex and gender, and just 5% of global research and development funding went to women's health research in 2020.

Kelleher framed the problem in plain terms, noting that decades of medical research built around the male body have left gaps in how diseases, medicines and treatments affect women — gaps that translate into delayed diagnoses and difficulty accessing the right treatment.

What it changes for patients — and what remains symbolic

For patients, the most tangible promise is money and metrics. The report asks the Commission to route targeted funding through existing EU programmes, including Horizon Europe and the European Competitiveness Fund, and to attach clear indicators and monitoring to any new strategy. Renew Europe cites estimates that closing investment gaps in women's healthcare could add roughly $1 trillion to the global economy annually by 2040 — a figure the group uses to argue that gender-responsive health policy is also industrial policy.

On rights, Parliament renewed its backing for the European Citizens' Initiative "My Voice, My Choice" and reiterated the call for sexual and reproductive health and rights — including the right to safe, legal and accessible abortion — to be written into the EU Charter of Fundamental Rights. That language is political, not legislative: an adopted Parliament report does not bind member states on abortion access, and national rules still govern clinical practice on the ground.

What to watch next

• Whether the European Commission tables a standalone women's health strategy with its own budget line, rather than scattering gender-equality provisions across existing programmes.
• How Horizon Europe and the European Competitiveness Fund adjust calls for proposals to require sex-disaggregated reporting and dedicated women's-health funding streams.
• Whether Parliament's Charter language gathers enough cross-party support to survive a Council vote — the harder political test than this week's plenary.

For readers tracking contraceptive access, maternal care, or abortion services, the practical takeaway is that EU-level pressure is now pointed squarely at clinical trial design and sex-specific data collection. That work will take years to filter into national clinical guidelines — but the baseline claim that women's health is a "major health priority" is now on the parliamentary record, and advocates have a concrete document to hold policymakers to.